Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
Por:
Vandekerckhove, L, Fox, J, Mora-Peris, B, Navarro, J, Allard, SD, Uriel, AJ, Guillén, SM, Boffito, M, Post, FA, Estrada, V, Mothe, B, Delporte, M, Benlahrech, A, Rahman, H, Clubley, J, Treveil, A, Chamberlain, J, Harrison, R, Hock, M, Yuan, Y, Wustner, J, Moureau, S, Whale, AD, Wallace, Z, Singh, PK, Titanji, K, Dorrell, L and Fidler, S
Publicada:
31 ene 2026
Resumen:
HIV persistence in reservoirs despite antiretroviral therapy (ART) is a barrier to a permanent cure. We present the affinity-enhanced TCR bispecific IMC-M113V as a potential therapeutic for targeted HIV reservoir elimination. Preclinical studies demonstrate that IMC-M113V redirects T cells towards cells expressing the variable viral peptide, Gag77-85, presented by HLA-A*02:01 at low copy number, without binding to HIV-negative cells. Here, we conduct a first-in-human, open-label single ascending dose study of IMC-M113V (1.6-15 & micro;g) in twelve HLA-A*02:01-positive males living with HIV on suppressive ART (EudraCT number 2021-002008-11). Participants receive one intravenous infusion of IMC-M113V on Day 1 and are monitored through Day 29 to evaluate safety, tolerability (primary endpoints) and pharmacodynamic (PD) activity (secondary endpoint). IMC-M113V is well tolerated and not associated with any serious adverse event. PD activity is dose-dependent and strongest in participants with highly IMC-M113V-sensitive Gag77-85 variant sequences. Thus, we provide a promising foundation to evaluate multiple and higher doses of IMC-M113V as a strategy for achieving ART-free virological control.
Filiaciones:
Vandekerckhove, L:
Univ Ghent, HIV Cure Res Ctr, Dept Internal Med & Pediat, Ghent, Belgium
Fox, J:
Guys & St Thomas NHS Fdn Trust, London, England
Kings Coll London, London, England
Mora-Peris, B:
Imperial Coll London, Dept Infect Dis, London, England
Imperial Coll Natl Inst Hlth Res Biomed Res Ctr, London, England
Navarro, J:
Hosp Univ Vall dHebron, Infect Dis Dept, Barcelona, Spain
Inst Recerca Vall dHebron, Barcelona, Spain
Allard, SD:
Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Internal Med & Infect Dis, Brussels, Belgium
Uriel, AJ:
Manchester Univ NHS Fdn Trust, North Manchester Gen Hosp, Reg Infect Dis Unit, Manchester, England
Guillén, SM:
Ramon & Cajal Univ Hosp, Dept Infect Dis, Madrid, Spain
Alcala Univ, IRYCIS, CIBERINFEC, Madrid, Spain
Boffito, M:
Chelsea & Westminster Hosp, Dept HIV Med, London, England
Post, FA:
Kings Coll Hosp NHS Fdn Trust, Dept Sexual Hlth & HIV, London, England
Estrada, V:
Univ Complutense, Hosp Clin San Carlos IdiSSC, Ciberinfec, Madrid, Spain
:
Inst Hlth Sci Res Germans Trias & Pujo IGTP, Dept Infect Dis, Badalona, Spain
Inst Hlth Sci Res Germans Trias & Pujo IGTP, Fundacio Lluita laSida, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Badalona, Spain
CIBERINFEC, Madrid, Spain
UVic UCC, Vic, Spain
Delporte, M:
Univ Ghent, HIV Cure Res Ctr, Dept Internal Med & Pediat, Ghent, Belgium
Benlahrech, A:
Immunocore Ltd, Abingdon, England
Rahman, H:
Immunocore Ltd, Abingdon, England
Clubley, J:
Immunocore Ltd, Abingdon, England
Treveil, A:
Immunocore Ltd, Abingdon, England
Chamberlain, J:
Immunocore Ltd, Abingdon, England
Harrison, R:
Immunocore Ltd, Abingdon, England
Hock, M:
Immunocore Ltd, Abingdon, England
Yuan, Y:
Immunocore Ltd, Gaithersburg, MD USA
Wustner, J:
Immunocore Ltd, Gaithersburg, MD USA
Moureau, S:
Immunocore Ltd, Abingdon, England
Whale, AD:
Immunocore Ltd, Abingdon, England
Wallace, Z:
Immunocore Ltd, Abingdon, England
Singh, PK:
Immunocore Ltd, Abingdon, England
Titanji, K:
Immunocore Ltd, Gaithersburg, MD USA
Dorrell, L:
Immunocore Ltd, Abingdon, England
Fidler, S:
Imperial Coll London, Dept Infect Dis, London, England
Imperial Coll Natl Inst Hlth Res Biomed Res Ctr, London, England
Green Submitted, gold
|